By Cocer Peptides 
Watanni 1 da suka gabata
DUKKANIN LABARI DA BAYANIN KYAUTATAWA DA AKE BAYAR A WANNAN SHAFIN KAWAI DOMIN WATSA BAYANI NE DA MANUFOFIN ILIMI.
Kayayyakin da aka bayar akan wannan gidan yanar gizon an yi niyya ne kawai don binciken in vitro. Binciken in vitro (Latin: *a cikin gilashi*, ma'ana a cikin gilashin gilashi) ana gudanar da shi a wajen jikin mutum. Waɗannan samfuran ba magunguna ba ne, Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da su ba, kuma dole ne a yi amfani da su don hanawa, magani, ko warkar da kowane yanayi na likita, cuta, ko cuta. Doka ta haramta shigar da waɗannan samfuran cikin jikin mutum ko dabba ta kowace hanya.
Dubawa
Tirzepatid, sabon magani, ya sami kulawa mai mahimmanci a fagen maganin ciwon sukari. Ita ce farkon dual agonist a duniya na mai karɓar glucagon-kamar peptide-1 (GLP-1) da mai karɓar insulinotropic polypeptide (GIP) mai dogaro da glucose. Ta hanyar aikin sa na musamman, yana kwaikwayon tasirin GLP-1 da GIP, yana ba da sabon zaɓi don sarrafa glucose na jini.
Hoto 1 Hanyoyin aikin Tirzepatid a cikin jikin mutum.
Tsarin Aiki
Tsarin insulin da glucagon: Tirzepatid yana ƙara haɓakar insulin kuma yana rage sakin glucagon ta hanyar dogaro da glucose. Lokacin da matakan glucose na jini ya tashi, Tirzepatid yana haifar da ƙwayoyin beta na pancreatic don ɓoye ƙarin insulin, ta haka yana hanzarta ɗaukar glucose da amfani da rage matakan glucose na jini; Hakanan yana hana fitar da sinadarin glucagon, yana rage fitowar glucose na hanta, yana kara daidaita matakan glucose na jini. Wannan tsarin tsari na nau'i-nau'i biyu yana taimakawa wajen kiyaye ma'aunin glucose na jini mai tsauri, yadda ya kamata yana rage duka azumi da matakan glucose na jini.
Haɓaka satiety da asarar nauyi: Wannan magani na iya haɓaka satiety, yana jagorantar marasa lafiya don rage cin abinci kuma ta haka rasa nauyi. Rage nauyi yana da mahimmanci ga marasa lafiya masu fama da ciwon sukari na 2, saboda yawan kiba yana da alaƙa da juriya na insulin. Ta hanyar rage nauyi, Tirzepatid yana taimakawa inganta haɓakar insulin, yana sa jiki ya fi karɓar insulin kuma ta haka yana da kyau sarrafa matakan glucose na jini. Bugu da ƙari, asarar nauyi yana taimakawa rage haɗarin rikitarwa kamar cututtukan zuciya da jijiyoyin jini a cikin masu ciwon sukari.
Jinkirta zubar da ciki: Tirzepatid yana jinkirta zubar da ciki, yana tsawaita lokacin da abinci ya rage a ciki kuma yana jinkirta shigarsa cikin karamar hanji, don haka yana hana saurin girma a cikin matakan sukari na jini. Wannan tasirin yana taimakawa daidaita jujjuyawar sukari na jini, musamman ta yadda yakamata sarrafa kololuwar sukarin jini na postprandial, ƙirƙirar yanayi masu kyau don daidaitawar sukarin jini.
Haɓaka alamomi na rayuwa: Baya ga tasirin sa akan sukarin jini da nauyi, Tirzepatid kuma yana nuna sakamako mai kyau a cikin haɓaka matakan lipid da sauran alamun rayuwa. Nazarin asibiti ya nuna cewa yana taimakawa rage ƙananan ƙwayoyin lipoprotein (LDL) cholesterol da matakan triglyceride, haɓaka lafiyar lafiyar jiki gabaɗaya da ƙara rage haɗarin cututtukan zuciya da jijiyoyin jini a cikin masu ciwon sukari.
Aikace-aikace
A cikin cikakken SURPASS da SURMOUNT babban nazarin asibiti na Mataki na III, Tirzepatid ya nuna ingantaccen sarrafa glucose na jini. Idan aka kwatanta da placebo, Tirzepatid ya rage matakan haemoglobin A1c (HbA1c) sosai yayin da yake nuna kyakkyawan tasirin asarar nauyi. Ingancin sa ya zarce na GLP-1 da aka amince da su a halin yanzu. A wasu gwaje-gwajen, marasa lafiya da aka yi musu magani tare da Tirzepatid sun sami raguwa mafi girma a cikin matakan HbA1c da hasara mai ma'ana, yana nuna a fili ingancinsa da fifiko a cikin sarrafa glycemic da sarrafa nauyi.
Jiyya na Nau'in Ciwon sukari na 2: A matsayin haɗin kai ga abinci da motsa jiki, Tirzepatid yana ba da zaɓin magani mai inganci ga marasa lafiya da nau'in ciwon sukari na 2. Ko ana amfani da shi azaman magani ɗaya ko a haɗe tare da sauran magungunan antidiabetic, Tirzepatid yana inganta sarrafa glucose na jini sosai.
Kammalawa
A taƙaice, Tirzepatid yana nuna fa'idodi a cikin sarrafa glucose na jini saboda keɓaɓɓen tsarin aikin sa da kuma kyakkyawan aiki a cikin gwaje-gwajen asibiti. Ba wai kawai yana rage matakan glucose na jini yadda ya kamata ba amma kuma yana taka rawa mai kyau a cikin sarrafa nauyi da haɓaka alamomin rayuwa.
Sources
[1] Sood A, Kaur P, Syed O, et al. Juya kulawar ciwon sukari: bayyana yuwuwar tirzepatide a cikin sarrafa glycemic da bayan [J]. Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararru, 2024,17 (3): 235-246.DOI: 10.1080/17512433.2024.2310070.
[2] Wong E, Cope R, Dima L, et al. Tirzepatid: A Dual Glucose-dogara Insulinotropic Polypeptide da Glucagon-Kamar Peptide-1 Agonist don Gudanar da Nau'in 2 Ciwon sukari Mellitus[J]. Jaridar Amirka ta Therapeutics, 2023,30 (1): e26-e35.DOI: 10.1097/MJT.0000000000001588.
[3] Kumar D, Harshidha D, Mousigan M, et al. Bayani akan Tirzepatid, Jiyya na Dual-Niyya don Ciwon sukari da Kiba[J]. Jarida ta kasa da kasa na Bincike da Ci gaba, 2022,7:983.DOI:10.5281/zenodo.7420605.
[4] Chavda VP, Ajabiya J, Teli D, et al. Tirzepatid, Sabon Zamani na Jiyya Biyu-Niyya don Ciwon sukari da Kiba: Karamin-Bita[J]. Molecules, 2022,27(13).DOI:10.3390/molecules27134315.
[5] Forzano I, Varzideh F, Avvisato R, et al. Tirzepatid: Sabunta Tsare-tsare[J]. Jarida ta Duniya na Kimiyyar Kwayoyin Halitta, 2022,23(23).DOI:10.3390/ijms232314631.
Samfura akwai don amfani da bincike kawai:
